Global medical technology company BD has completed the acquisition of privately held Scanwell Health, a provider in smartphone-enabled at-home medical tests.
BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor At-Home COVID-19 Test, an at-home COVID-19 test that uses a smartphone camera and app to capture and interpret results, designed to eliminate the human subjectivity in other visually read at-home antigen tests.
Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases including COVID-19/influenza A+B, group A strep and additional menu for detecting infections and managing chronic disease.
“The COVID-19 pandemic has accelerated the shift to new care settings, and BD is ready to deliver a smart, connected at-home diagnostic ecosystem to support traditional and telehealth providers and consumers,” says Dave Hickey, president of Life Sciences for BD. “This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future.”
The BD Veritor At-Home COVID-19 Test also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities, and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app.
The BD Veritor At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA).
The transaction is expected to be immaterial to BD’s fiscal 2022 financial results. Scanwell financial results will be reported under the Integrated Diagnostic Solutions business within the Life Sciences segment.
Featured image: BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor™ At-Home COVID-19 Test,* the first at-home COVID-19 test that uniquely uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. *EUA authorized by FDA. Photo: BD